Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
National Cancer Institute (NCI)
BioNTech SE
AbbVie
Bristol-Myers Squibb
Cancer Research UK
AbbVie
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
TJ Biopharma Co., Ltd.
Eikon Therapeutics
Regeneron Pharmaceuticals
Rigshospitalet, Denmark
Cancer Research UK
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Alpha Biopharma (Jiangsu) Co., Ltd.
Swiss Cancer Institute
Hansoh BioMedical R&D Company
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Medicine Invention Design, Inc
PhytoHealth Corporation
SWOG Cancer Research Network
Sun Yat-sen University
Hunan Province Tumor Hospital
Canadian Cancer Trials Group
Chang Gung Memorial Hospital
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
University Hospital, Brest
Merck Sharp & Dohme LLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Shanghai Pulmonary Hospital, Shanghai, China
Biocad
Lumos Pharma
Canadian Cancer Trials Group
Chungbuk National University
Tianjin Medical University Cancer Institute and Hospital
Intergroupe Francophone de Cancerologie Thoracique
Royal Marsden NHS Foundation Trust
Clovis Oncology, Inc.
Guangdong Association of Clinical Trials
European Organisation for Research and Treatment of Cancer - EORTC
Dong-A University Hospital
AIO-Studien-gGmbH
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Guangdong Provincial People's Hospital
Intergroupe Francophone de Cancerologie Thoracique
Chinese Society of Lung Cancer
Transgene
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.